Eleftherios P Diamandis
Overview
Explore the profile of Eleftherios P Diamandis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
632
Citations
12120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Stavraka C, Chauhan J, Crescioli S, McSweeney S, Pope A, Gillett C, et al.
Allergy
. 2025 Mar;
PMID: 40045925
Background: IgE antibodies directed against cancer antigens have demonstrated potent anti-tumour effects in pre-clinical studies. MOv18 IgE, the first-in-class IgE recognising the cancer antigen folate receptor alpha (FRα), showed preliminary...
3.
Chatanaka M, Diamandis E
Clin Chem Lab Med
. 2025 Jan;
PMID: 39819368
Cancer screening is considered to be a major strategy for combatting cancer. The United States Preventive Services Task Force (USPSTF) recommends screening for five cancers, but the strength of evidence...
4.
Janket S, Chatanaka M, Sohaei D, Tamimi F, Meurman J, Diamandis E
Cells
. 2024 Nov;
13(22).
PMID: 39594592
Recent clinical trials using synthetic incretin hormones, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have demonstrated that these treatments ameliorated many complications related to obesity, emphasizing...
5.
Chatanaka M, Diamandis E
EJIFCC
. 2024 Nov;
35(3):206-209.
PMID: 39507573
Introduction: Most circulating cancer and other disease biomarker concentrations increase during disease progression, roughly correlating with tumor burden or disease severity. During the biomarker discovery phase, several studies (some published...
6.
Chatanaka M, Yousef G, Diamandis E
Clin Chem Lab Med
. 2024 Sep;
63(3):499-506.
PMID: 39301604
The biotechnology company Grail developed a non-invasive blood test (Galleri test) which is claimed to detect 50 types of cancer at early and potentially curable stages. The initially promising results...
7.
Chatanaka M, Diamandis E
EJIFCC
. 2024 Sep;
35(2):132-135.
PMID: 39247660
Introduction: The majority of the high-grade serous ovarian cancer (HGSOC) cases are diagnosed late, preventing effective treatment and therapy. We examine the feasibility of using EVA (Early oVArian cancer), a...
8.
Feilotter H, Bruce C, Diamandis E, Chatanaka M, Yousef G
Crit Rev Clin Lab Sci
. 2024 Jul;
62(1):1-8.
PMID: 39084247
The journey of translating a molecular discovery into the clinic involves multiple steps and requires planning, time, effort, and money. In this review, we provide a quick guide on the...
9.
Wurtz L, Knyazhanskaya E, Sohaei D, Prassas I, Pittock S, Willrich M, et al.
Clin Proteomics
. 2024 Jun;
21(1):42.
PMID: 38880880
Background: Multiple sclerosis (MS) is a clinically and biologically heterogenous disease with currently unpredictable progression and relapse. After the development and success of neurofilament as a cerebrospinal fluid (CSF) biomarker,...
10.
Ghorbani A, Chatanaka M, Avery L, Wang M, Brown J, Cohen R, et al.
Clin Proteomics
. 2024 Jun;
21(1):41.
PMID: 38879494
Background: Gliomas are aggressive malignant tumors, with poor prognosis. There is an unmet need for the discovery of new, non-invasive biomarkers for differential diagnosis, prognosis, and management of brain tumors....